BACKGROUND: Despite better accessibility of the effective lipid-lowering therapies, only about 20% of patients at very high cardiovascular risk achieve the low-density lipoprotein cholesterol (LDL-C) goals. There is a large disparity between European countries with worse results observed for the Central and Eastern Europe (CEE) patients. One of the main reasons for this ineffectiveness is therapeutic inertia related to the limited access to appropriate therapy and suitable dosage intensity. Thus, we aimed to compare the differences in physicians' therapeutic decisions on alirocumab dose selection, and factors affecting these in CEE countries vs. other countries included in the ODYSSEY APPRISE study. METHODS: ODYSSEY APPRISE was a prospective, single-arm, phase 3b open-label (≥12 weeks to ≤30 months) study with alirocumab. Patients received 75 or 150 mg of alirocumab every 2 weeks, with dose adjustment during the study based on physician's judgment. The CEE group in the study included Czechia, Greece, Hungary, Poland, Romania, Slovakia, and Slovenia, which we compared with the other nine European countries (Austria, Belgium, Denmark, Finland, France, Germany, Italy, Spain, and Switzerland) plus Canada. RESULTS: A total of 921 patients on alirocumab were involved [modified intention-to-treat (mITT) analysis], including 114 (12.4%) subjects from CEE countries. Therapy in CEE vs. other countries was numerically more frequently started with lower alirocumab dose (75 mg) at the first visit (74.6 vs. 68%, p = 0.16). Since week 36, the higher dose was predominantly used in CEE patients (150 mg dose in 51.6% patients), which was maintained by the end of the study. Altogether, alirocumab dose was significantly more often increased by CEE physicians (54.1 vs. 39.9%, p = 0.013). Therefore, more patients achieved LDL-C goal at the end of the study (<55 mg/dl/1.4 mmol/L and 50% reduction of LDL-C: 32.5% vs. 28.8%). The only factor significantly influencing the decision on dose of alirocumab was LDL-C level for both countries' groups (CEE: 199.2 vs. 175.3 mg/dl; p = 0.019; other: 205.9 vs. 171.6 mg/dl; p < 0.001, for 150 and 75 mg of alirocumab, respectively) which was also confirmed in multivariable analysis (OR = 1.10; 95% CI: 1.07-1.13). CONCLUSIONS: Despite larger unmet needs and regional disparities in LDL-C targets achievement in CEE countries, more physicians in this region tend to use the higher dose of alirocumab, they are more prone to increase the dose, which is associated with a higher proportion of patients reaching LDL-C goals. The only factor that significantly influences decision whether to increase or decrease the dose of alirocumab is LDL-C level.

1st Department of Propaedeutic Internal Medicine Medical School National and Kapodistrian University of Athens Laiko General Hospital Athens Greece

2nd Department of Cardiology of the East Slovak Institute of Cardiovascular Disease and Faculty of Medicine PJ Safarik University Kosice Slovakia

3rd Department of Medicine Department of Endocrinology and Metabolism of the 1st Faculty of Medicine Charles University and General University Hospital Prague Czechia

Cardiometabolic Center Metropolitan Hospital Piraeus Greece

Cardiovascular Rehabilitation Clinic Clinical Rehabilitation Hospital Iasi Romania

Cardiovascular Research Centre University of Zielona Gora Zielona Gora Poland

Ciccarone Center for the Prevention of Cardiovascular Disease Johns Hopkins University School of Medicine Baltimore MD United States

Department of Cardiology and Congenital Diseases of Adults Polish Mother's Memorial Hospital Research Institute Lodz Poland

Department of Cardiology Elias Emergency University Hospital Carol Davila University of Medicine and Pharmacy Bucharest Romania

Department of Epidemiology and Health Promotion School of Public Health Center of Postgraduate Medical Education Warsaw Poland

Department of Internal Medicine and Geriatric Cardiology Center of Postgraduate Medical Education Warsaw Poland

Department of Medical Specialties 1 Grigore T Popa University of Medicine and Pharmacy Iasi Romania

Department of Population Health Monitoring and Analysis National Institute of Public Health NIH National Research Institute Warsaw Poland

Department of Preventive Cardiology and Lipidology Medical University of Lodz Lodz Poland

Division of Metabolism Department of Internal Medicine Faculty of Medicine University of Debrecen Debrecen Hungary

Faculty of Medical Sciences in Katowice Medical University of Silesia Katowice Poland

Sanofi Bridgewater NJ United States

Sanofi Warsaw Poland

The 3rd Department of Internal Medicine Metabolic Care and Gerontology Charles University and University Hospital in Hradec Králové Hradec Králové Czechia

University Clinical Center Maribor Maribor Slovenia

Zobrazit více v PubMed

Vasan RS, Enserro DM, Xanthakis V, Beiser AS, Seshadri S. Temporal trends in the remaining lifetime risk of cardiovascular disease among middle-aged adults across 6 decades: the Framingham study. Circulation. (2022) 145(17):1324–38. 10.1161/CIRCULATIONAHA.121.057889 PubMed DOI PMC

Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM, et al. Global burden of cardiovascular diseases and risk factors, 1990–2019: update from the GBD 2019 study. J Am Coll Cardiol. (2020) 76(25):2982–3021. Erratum in: J Am Coll Cardiol. (2021) 77(15):1958–9. 10.1016/j.jacc.2020.11.010 PubMed DOI PMC

Surma S, Banach M. Fibrinogen and atherosclerotic cardiovascular diseases-review of the literature and clinical studies. Int J Mol Sci. (2021) 23(1):193. 10.3390/ijms23010193 PubMed DOI PMC

Khan MA, Hashim MJ, Mustafa H, Baniyas MY, Al Suwaidi SKBM, AlKatheeri R, et al. Global epidemiology of ischemic heart disease: results from the global burden of disease study. Cureus. (2020) 12(7):e9349. 10.7759/cureus.9349 PubMed DOI PMC

GBD 2019 Stroke Collaborators. Global, regional, and national burden of stroke and its risk factors, 1990–2019: a systematic analysis for the global burden of disease study 2019. Lancet Neurol. (2021) 20(10):795–820. 10.1016/S1474-4422(21)00252-0 PubMed DOI PMC

Banach M, Burchardt P, Chlebus K, Dobrowolski P, Dudek D, Dyrbuś K, et al. PoLA/CFPiP/PCS/PSLD/PSD/PSH guidelines on diagnosis and therapy of lipid disorders in Poland 2021. Arch Med Sci. (2021) 17(6):1447–547. 10.5114/aoms/141941 PubMed DOI PMC

Grundy SM. Dyslipidaemia in 2015: advances in treatment of dyslipidaemia. Nat Rev Cardiol. (2016) 13(2):74–5. 10.1038/nrcardio.2015.208 PubMed DOI

Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European atherosclerosis society consensus panel. Eur Heart J. (2017) 38(32):2459–72. 10.1093/eurheartj/ehx144 PubMed DOI PMC

Ray KK, Molemans B, Schoonen WM, Giovas P, Bray S, Kiru G, et al. DA VINCI study. EU-wide cross-sectional observational study of lipid-modifying therapy use in secondary and primary care: the DA VINCI study. Eur J Prev Cardiol. (2021) 28(11):1279–89. 10.1093/eurjpc/zwaa047 PubMed DOI

Vrablik M, Seifert B, Parkhomenko A, Banach M, Jóźwiak JJ, Kiss RG, et al. Lipid-lowering therapy use in primary and secondary care in central and Eastern Europe: DA VINCI observational study. Atherosclerosis. (2021) 334:66–75. 10.1016/j.atherosclerosis.2021.08.035 PubMed DOI

Gaudet D, Lopez-Sendon JL, Averna M, Bigot G, Banach M, Letierce A, et al. Safety and efficacy of alirocumab in a real-life setting: the ODYSSEY APPRISE study. Eur J Prev Cardiol. (2022) 28(17):1864–72. 10.1093/eurjpc/zwaa097 PubMed DOI

Banach M, López-Sendon JL, Averna M, Cariou B, Loy M, Manvelian G, et al. Treatment adherence and effect of concurrent statin intensity on the efficacy and safety of alirocumab in a real-life setting: results from ODYSSEY APPRISE. Arch Med Sci. (2021) 18(2):285–92. 10.5114/aoms/143476 PubMed DOI PMC

Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. (2020) 41(1):111–88. 10.1093/eurheartj/ehz455 PubMed DOI

Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. (1972) 18:499–502. 10.1093/clinchem/18.6.499 PubMed DOI

Banach M, Penson PE, Vrablik M, Bunc M, Dyrbus K, Fedacko J, et al. Optimal use of lipid-lowering therapy after acute coronary syndromes: a position paper endorsed by the international lipid expert panel (ILEP). Pharmacol Res. (2021) 166:105499. 10.1016/j.phrs.2021.105499 PubMed DOI

Banach M, Reiner Z, Cicero AFG, Sabouret P, Viigimaa M, Sahebkar A, et al. 2022: the year in cardiovascular disease—the year of upfront lipid lowering combination therapy. Arch Med Sci. (2022) 18(6):1429–34. 10.5114/aoms/156147 PubMed DOI PMC

Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, et al. 2021 ESC guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. (2021) 42(34):3227–337. 10.1093/eurheartj/ehab484 PubMed DOI

Dyrbus K, Gasior M, Desperak P, Nowak J, Osadnik T, Banach M. Characteristics of lipid profile and effectiveness of management of dyslipidaemia in patients with acute coronary syndromes—data from the TERCET registry with 19,287 patients. Pharmacol Res. (2019) 139:460–6. 10.1016/j.phrs.2018.12.002 PubMed DOI

Cífková R, Bruthans J, Wohlfahrt P, Krajčoviechová A, Šulc P, Jozífová M, et al. 30-year trends in major cardiovascular risk factors in the Czech population, Czech MONICA and Czech post-MONICA, 1985–2016/17. PLoS One. (2020):15:e0232845. 10.1371/journal.pone.0232845 PubMed DOI PMC

Nowowiejska-Wiewióra A, Wita K, Mędrala Z, Tomkiewicz-Pająk L, Bujak K, Mizia-Stec K, et al. Dyslipidemia treatment and attainment of LDL-cholesterol treatment goals in patients participating in the managed care for acute myocardial infarction survivors program. Kardiol Pol. (2023) 81(4):359–65. 10.33963/KP.a2023.0045 PubMed DOI

Reiner Z, Sonicki Z, Tedeschi-Reiner E. Physicians’ perception, knowledge and awareness of cardiovascular risk factors and adherence to prevention guidelines: the PERCRO-DOC survey. Atherosclerosis. (2010) 213:598–603. 10.1016/j.atherosclerosis.2010.09.014 PubMed DOI

Ding R, Ye P, Zhao S, Zhao D, Yan X, Dong Y, et al. Effect of physician characteristics and knowledge on the quality of dyslipidemia management and LDL-C target goal achievement in China: subgroup analysis of the dyslipidemia international study. J Glob Health. (2017) 7(2):020702. 10.7189/jogh.07.020702 PubMed DOI PMC

Arnold SV, Kosiborod M, Tang F, Zhao Z, Maddox TM, McCollam PL, et al. Patterns of statin initiation, intensification, and maximization among patients hospitalized with an acute myocardial infarction. Circulation. (2014) 129:1303–9. 10.1161/CIRCULATIONAHA.113.003589 PubMed DOI PMC

Banach M, Surma S, Reiner Z, Katsiki N, Penson PE, Fras Z, et al. Personalized management of dyslipidemias in patients with diabetes-it is time for a new approach (2022). Cardiovasc Diabetol. (2022) 21(1):263. 10.1186/s12933-022-01684-5 PubMed DOI PMC

Banach M, Penson PE, Farnier M, Fras Z, Latkovskis G, Laufs U, et al. Bempedoic acid in the management of lipid disorders and cardiovascular risk. 2023 position paper of the International Lipid Expert Panel (ILEP). Prog Cardiovasc Dis. (2023) S0033−0620(23):00026–9. 10.1016/j.pcad.2023.03.001 PubMed DOI

Dobrowolski P, Prejbisz A, Kuryłowicz A, Baska A, Burchardt P, Chlebus K, et al. Metabolic syndrome—a new definition and management guidelines: a joint position paper by the Polish society of hypertension, Polish society for the treatment of obesity, Polish lipid association, Polish association for study of liver, Polish society of family medicine, Polish society of lifestyle medicine, division of prevention and epidemiology Polish cardiac society, “club 30” Polish cardiac society, and division of metabolic and bariatric surgery society of Polish surgeons. Arch Med Sci. (2022) 18(5):1133–56. 10.5114/aoms/152921 PubMed DOI PMC

Banach M, Kaźmierczak J, Mitkowski P, Wita K, Broncel M, Gąsior M, et al. Which patients at risk of cardiovascular disease might benefit the most from inclisiran? Polish experts’ opinion. The compromise between EBM and possibilities in healthcare. Arch Med Sci. (2022) 18(3):569–76. 10.5114/aoms/147435 PubMed DOI PMC

Altschmiedová T, Todorovová V, Šnejdrlová M, Šatný M, Češka R. PCSK9 Inhibitors in real-world practice: analysis of data from 314 patients and 2 years of experience in a center of preventive cardiology. Curr Atheroscler Rep. (2022) 24(5):357–63. 10.1007/s11883-022-01008-8 PubMed DOI PMC

2024 Recommendations on the Optimal Use of Lipid-Lowering Therapy in Established Atherosclerotic Cardiovascular Disease and Following Acute Coronary Syndromes: A Position Paper of the International Lipid Expert Panel (ILEP)